All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.

Retinitis Pigmentosa

Retinal Degeneration

Cannabis

single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)

cannabis

Hadassah Medical Center

The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients

A Controlled Study of the Effect of Cannabis on Visual Functions in Healthy Subjects and in Retinitis Pigmentosa Patients

Hadas MECHOULAM

senior physician

Hadassah Medical Organization

Hebrew University of Jerusalem

Arm 1 - healthy subjects. Arm 2 - subjects with retinitis pigmentosa All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.

Electrophysiology will be analyzed by a blinded investigator.

Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Avidekel oil (6-to-1 ratio of CBD to THC)

Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)

Patients with spasticity and dystonia due to cerebral palsy will consume Avidekel oil (6-to-1 ratio of CBD to THC)

Patients with spasticity and dystonia due to cerebral palsy will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)

Spasticity

Dystonia

Avidekel oil

Enriched Avidekel cannabis oil 20:1 CBD:THC

Enriched Avidekel oil

Dr. Lubov Blumkin

The Effects of Cannabis on Dystonia and Spasticity on Pediatric Patients

A Randomized Double Blind Study of Cannabis on Dystonia and Spasticity in Pediatric Patients

Luba Blumkin

Dr. Luba Blumkin

Wolfson Medical Center

Huntington's Disease

Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.

delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)

Placebo, One spray per day, up to a maximum of 12 sprays per day.

Placebo

Hospital Universitario Ramón y Cajal

Neuroprotection by Cannabinoids in Huntington's Disease

A Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial to Asses Neuroprotection by Cannabinoids in Huntington's Disease

UHDRS scale scores from the following perspectives: motor, cognitive, psychiatric and functional.

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

GW Pharmaceuticals Ltd.

matched capsules
placebo: matched for physical appearance

2 gm/day
citicoline: 2 gm/day, 8 weeks treatment

neurodegenerative diseases/cannabas

The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients

The Effects of Cannabis on Dystonia and Spasticity on Pediatric Patients

Neuroprotection by Cannabinoids in Huntington's Disease

Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht